Meghraj Vivekanand Suryawanshi | Pharmaceutics | Innovative Research Award

Innovative Research Award

Meghraj Vivekanand Suryawanshi
Affiliation Savitribai Phule Pune University
Country India
Scopus ID 58037948200
Documents 48
Citations 104
h-index 5
Subject Area Pharmaceutics
Event Indian Scientist Awards
ORCID 0000-0003-3958-2813

Meghraj Vivekanand Suryawanshi

Savitribai Phule Pune University, India

Meghraj Vivekanand Suryawanshi has contributed to the field of Pharmaceutics through research activities reflected in indexed publications, citations, and measurable scholarly impact. His academic profile demonstrates sustained engagement in pharmaceutical sciences and related research domains, supporting scientific knowledge dissemination and interdisciplinary collaboration.[1][2]

Abstract

This article presents an academic overview of Meghraj Vivekanand Suryawanshi and his scholarly contributions within the field of Pharmaceutics. The profile highlights publication activity, citation performance, research engagement, and academic impact indicators documented through internationally recognized indexing platforms. The assessment considers research productivity, contribution to pharmaceutical sciences, and relevance to innovation-oriented scientific recognition programs.[1]

Keywords

Pharmaceutics, Drug Delivery Systems, Pharmaceutical Research, Scientific Innovation, Research Impact, Scholarly Publications, Citation Analysis, Academic Recognition, Pharmaceutical Sciences, Innovative Research Award.

Introduction

Research in pharmaceutics plays a fundamental role in improving therapeutic outcomes, formulation technologies, drug delivery mechanisms, and pharmaceutical manufacturing processes. Academic researchers contribute to the advancement of healthcare through experimental investigations, translational research, and dissemination of scientific findings. Meghraj Vivekanand Suryawanshi’s scholarly profile reflects active participation in these efforts through publication and citation records indexed in major academic databases.[1]

Research Profile

Meghraj Vivekanand Suryawanshi is affiliated with Savitribai Phule Pune University, a recognized institution engaged in higher education and scientific research. His documented scholarly profile includes research publications indexed in Scopus, demonstrating contributions to pharmaceutical sciences and related disciplines.[1]

  • Institutional Affiliation: Savitribai Phule Pune University.
  • Country of Research Activity: India.
  • Scopus Indexed Documents: 48.
  • Citation Count: 104.
  • h-index: 5.
  • Primary Subject Area: Pharmaceutics.

Research Contributions

The research contributions associated with this profile encompass pharmaceutical formulation studies, drug delivery approaches, evaluation methodologies, and related pharmaceutical investigations. Such work supports the broader objective of improving therapeutic effectiveness and scientific understanding within the pharmaceutical sector.[3]

  • Development and evaluation of pharmaceutical formulations.
  • Investigation of drug delivery technologies.
  • Research supporting pharmaceutical quality and efficacy assessment.
  • Contribution to peer-reviewed scientific literature.
  • Participation in collaborative and interdisciplinary research activities.

Publications

Publication activity serves as an important indicator of academic productivity. The available bibliometric profile demonstrates a record of peer-reviewed outputs that contribute to knowledge generation in pharmaceutical sciences and allied research areas.[1]

  1. Research articles indexed in international scientific databases.
  2. Studies related to pharmaceutical formulation and evaluation.
  3. Scientific communications supporting evidence-based pharmaceutical development.
  4. Collaborative publications contributing to interdisciplinary knowledge exchange.

Research Impact

Research impact may be evaluated through bibliometric indicators including publication volume, citation performance, and h-index metrics. With 48 indexed documents, 104 citations, and an h-index of 5, the profile demonstrates measurable scholarly visibility within the academic community.[1]

  • Evidence of sustained scholarly publication activity.
  • Research findings referenced by other investigators.
  • Contribution to scientific discourse within pharmaceutics.
  • Academic visibility reflected through citation metrics.

Award Suitability

The Innovative Research Award recognizes researchers whose scholarly activities contribute to scientific advancement and innovation. Based on the documented research profile, publication record, citation indicators, and engagement in pharmaceutical sciences, Meghraj Vivekanand Suryawanshi demonstrates attributes commonly associated with academic recognition programs emphasizing innovation, research productivity, and knowledge dissemination.[1][2]

Conclusion

Meghraj Vivekanand Suryawanshi’s academic profile reflects sustained participation in pharmaceutical research and scholarly publication. Through documented contributions in Pharmaceutics, indexed publications, citation performance, and measurable research indicators, the profile represents ongoing engagement with scientific inquiry and evidence-based knowledge development. These characteristics align with the objectives of professional research recognition initiatives such as the Innovative Research Award.[1]

References

  1. Scopus author details: Meghraj Vivekanand Suryawanshi, Author ID 58037948200. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58037948200
  2. Medicinal and Nutritional Importance of Hypericum perforatum in Human Health.https://link.springer.com/chapter/10.1007/978-981-95-3620-7_13
  3. Neuroprotective efficacy of Nyctanthes arbor-tristis in a rotenone-induced rat model of Parkinson’s disease

    https://www.sciencedirect.com/science/article/abs/pii/S0378874126006781?via%3Dihub

Mr. Akash Vikal | Nanotechnology and Advanced Materials | Innovative Research Award

Mr. Akash Vikal | Nanotechnology and Advanced Materials | Innovative Research Award

IFTM University, Moradabad, India

Akash Vikal is an emerging pharmaceutical researcher specializing in pharmaceutics, nanomedicine, advanced drug delivery systems, and cancer therapeutics. His academic and research contributions primarily focus on the development of innovative formulation strategies designed to improve therapeutic efficacy, targeted delivery, and patient outcomes. Through extensive research in liposomal formulations, nanocarriers, gene delivery systems, and ocular therapeutics, he has established himself as a promising young contributor to modern pharmaceutical sciences.His research portfolio reflects interdisciplinary expertise integrating pharmaceutical technology, nanotechnology, oncology, ophthalmic therapeutics, and translational medicine. With numerous peer-reviewed publications, book chapters, and scientific presentations, he has actively contributed to advancing pharmaceutical innovation and drug delivery research.

Professional Profile 

Education

Akash Vikal completed a Bachelor of Pharmacy (B.Pharm.) from Shri Gopichand College of Pharmacy with strong academic performance. He further pursued a Master of Pharmacy (M.Pharm.) in Pharmaceutics from ISF College of Pharmacy, where he specialized in advanced pharmaceutical formulation and drug delivery systems. His postgraduate research focused on the “Development and Characterization of Ferulic Acid and Docetaxel Loaded Liposomes Against Breast Cancer” under the guidance of Balak Das Kurmi.

Professional Experience

During his academic journey, Akash Vikal gained industrial exposure through internship training at HIS Pharmaceuticals Pvt. Ltd., where he developed practical knowledge related to pharmaceutical manufacturing and formulation processes. He has also actively contributed to scientific communication and peer-review activities, including reviewing submissions for reputed journals such as Dovepress journals Clinical Ophthalmology and Eye and Brain. In addition, he delivered an academic webinar on scientific writing and publication strategies for researchers and healthcare professionals.

Research Interest

He has contributed extensively to pharmaceutical and biomedical research through numerous publications in reputed international journals. His research covers areas such as metal-organic frameworks in drug delivery, PROTAC-based cancer therapy, nanoparticle-mediated antimicrobial strategies, CRISPR-assisted nanotechnology, nanocarrier systems for ocular therapeutics, and phytoconstituent-based anticancer therapies. Several of his works have been published in recognized journals including Applied Materials Today, Drug Delivery and Translational Research, AAPS PharmSciTech, Current Pharmaceutical Design, and Experimental Eye Research.

Award and Honor

Akash Vikal has received recognition for his academic and scientific contributions through participation in national and international conferences, workshops, and faculty development programs. He earned a Certificate of Excellence in Peer Reviewing for his contribution to academic quality enhancement. His involvement in intellectual property awareness programs, pharmaceutical research conferences, and specialized training workshops reflects his commitment to continuous professional development and scientific advancement.

Conclusion

Mebratu Tafesse Teferi demonstrates strong potential for the Best Researcher Award. His substantial academic qualifications, leadership experience, and dedication to educational research are commendable. His publications reflect significant contributions to Ethiopian education and leadership studies, making him a valuable candidate for the award. To further enhance his candidacy, Mebratu could focus on broadening his research scope, fostering international collaborations, and increasing his publication reach in globally recognized journals.

Publications Top Noted

  • Next-generation gene editing strategies in cancer: Integrating CRISPR, PROTACs, and advanced molecular technologies
    Authors: Akash Vikal, Rashmi Maurya, Pradeep Kumar, Navneet Verma, Arun Kumar Mishra
    Year: 2026
  • Liposomal Paclitaxel in Breast Cancer Therapy: Advances, Clinical Insights, and Future Perspectives
    Authors: Akash Vikal, Rashmi Maurya, Navneet Verma, Arun Kumar Mishra
    Year: 2026
  • A Mini-Review on Unlocking Cognitive Enhancement: An Innovative Strategy for Optimal Brain Functions
    Authors: Akash Vikal, Rashmi Maurya, Brij Bihari Patel, Preeti Patel, Manish Kumar, Balak Das Kurmi
    Year: 2025
  • Andrographis paniculata in Fatty Liver Disease: Mechanisms, Nanocarrier Approaches, and Therapeutic Potential
    Authors: Akash Vikal, Rashmi Maurya, Preeti Patel, Balak Das Kurmi
    Year: 2025
  • Development of Mucopenetrating Pegylated Liposomes Functionalized with Sodium Taurocholate for Enhanced Oral Insulin Delivery
    Authors: Akash Vikal, Rashmi Maurya, Balak Das Kurmi, S. Jindal, R. K. Narang
    Year: 2025
  • From Resistance to Response: Metallic Nanoparticles as Game Changers in Triple Negative Breast Cancer Therapy
    Authors: Akash Vikal, Rashmi Maurya, Preeti Patel, R. K. Narang, Balak Das Kurmi
    Year: 2025
  • Lutein as a Liver Guardian: Insights into its Hepatoprotective Mechanisms, Bioavailability, and Emerging Therapeutic Roles
    Authors: Akash Vikal, Rashmi Maurya, Preeti Patel, Balak Das Kurmi
    Year: 2025
  • Nanoemulsion Technology in Oral Drug Delivery: A Path to Enhanced Solubility and Bioavailability
    Authors: Akash Vikal, Rashmi Maurya, Preeti Patel, Balak Das Kurmi
    Year: 2025
  • Role of dePEGylation in Vesicular Carriers-Mediated Stimuli-Responsive Drug Delivery to Tumors
    Authors: Akash Vikal, Rashmi Maurya, Abhinav Vashishat, Taqdir Singh, Satyam Khare, Preeti Patel, Balak Das Kurmi
    Year: 2025